Acute Lymphoblastic Leukemia
Study: Re-engineered Gleevec reduces heart risks
Published in Cardiovascular Device Liability Week, December 23rd, 2007
The new study, which is slated to appear in the Dec. 3 issue of the Journal of Clinical Investigation, reports pre-clinical evidence that the newly re-engineered drug is just as effective as imatinib against gastrointestinal stromal tumor (GIST) and carries significantly less risk of heart...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Biomedicine
California Healthcare Institute Urges Congress to Extend R&D Tax Credit - Abdominal Aortic Aneurysm
Data on abdominal aortic aneurysm discussed by researchers at University of Nottingham - Abdominal Aortic Aneurysm
Research conducted at J.A. Hemmerich and co-authors has provided new information about abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Research from R. Mofidi et al broadens understanding of abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Research from Radboud University in the area of abdominal aortic aneurysm published - Abdominal Aortic Aneurysm
The Endovascular Aneurysm Repair (EVAR) Market Is Expected To Reach US$1.3 Billion by 2012 According To the Report 'Abdominal Aortic Aneurysm Endovascular Technology & Market Forecasts' - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
